NEO212

Small molecule

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Malignant Brain Tumors

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Non-Small Cell Lung Cancer

Competitive landscape

2 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Malignant Brain Tumors: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
NEO212: this drugStage not on recordSmall moleculeDNA (guanine N7 position)not yet gradedNo reviewed efficacy summary in this indication
Melphalan Hydrochloride (Evomela)
Approved(overall)
Small moleculeDNA (guanine N7 position)
Weak signal(overall)
No reviewed efficacy summary in this indication
TemozolomideApprovedSmall moleculeDNA alkylation (O6-guanine)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow NEO212 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02-28 · NCT06047379 · CT.gov ↗
What to watch

See the full readout calendar ↗